Literature DB >> 4585929

Proceedings: The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate.

D P Byar.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1973        PMID： 4585929     DOI： 10.1002/1097-0142(197311)32:5<1126::aid-cncr2820320518>3.0.co;2-c

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


× No keyword cloud information.
  64 in total

1.  The periodic health examination. Canadian Task Force on the Periodic Health Examination.

Authors: 
Journal:  Can Med Assoc J       Date:  1979-11-03       Impact factor: 8.262

Review 2.  Comparing how significantly the pharmacological treatment of genitourinary cancer in a non-curative setting affects endpoints of survival or response.

Authors:  David R Yates; Morgan Rouprêt
Journal:  World J Urol       Date:  2011-11-23       Impact factor: 4.226

3.  Androgen deprivation therapy for prostate cancer-review of indications in 2010.

Authors:  H Quon; D A Loblaw
Journal:  Curr Oncol       Date:  2010-09       Impact factor: 3.677

Review 4.  [Problems and principles of hormone therapy of advanced prostate cancer].

Authors:  J E Altwein; P Faul
Journal:  Klin Wochenschr       Date:  1990-04-02

5.  Molecular Basis of Steroid Action in the Prostate.

Authors:  Yuan-Shan Zhu
Journal:  Cellscience       Date:  2005-04-28

Review 6.  Treatment for PSA screen-detected prostate cancer: what are the options?

Authors:  R Tim D Oliver; David E Neal
Journal:  Nat Clin Pract Urol       Date:  2009-01-27

7.  Trends and racial differences in the use of androgen deprivation therapy for metastatic prostate cancer.

Authors:  April P Carson; Daniel L Howard; William R Carpenter; Yhenneko J Taylor; Sharon Peacock; Anna P Schenck; Paul A Godley
Journal:  J Pain Symptom Manage       Date:  2010-05       Impact factor: 3.612

8.  Simultaneous administration of pure antiandrogens, a combination necessary for the use of luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer.

Authors:  F Labrie; A Dupont; A Bélanger; J Emond; G Monfette
Journal:  Proc Natl Acad Sci U S A       Date:  1984-06       Impact factor: 11.205

9.  Buserelin treatment of advanced prostatic cancer: a phase II study.

Authors:  A Veronesi; G Lo Re; V Dal Bo; M D Magri; M Della Valentina; R Talamini; A Merlo; M Francini; S Monfardini
Journal:  Med Oncol Tumor Pharmacother       Date:  1989

10.  The course of metastatic disease originating from carcinoma of the prostate.

Authors:  S Plesnicar
Journal:  Clin Exp Metastasis       Date:  1985 Apr-Jun       Impact factor: 5.150
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.